big pharma
big pharma

Sobi Grows Product Portfolio With 2nd Deal

Swedish Orphan Biovitrum AB (STO: SOBI), an international specialty healthcare company dedicated to rare diseases, announced its acquisition of Dova Pharmaceuticals, Inc. for $867.7 million (65.3x revenue), or 27$ per share. Dova acquires, develops and commercializes drug candidates for diseases such as thrombocytopenia, a condition that leaves an individual with a low blood platelet count. Its […]

August Deal Flow Ebbs, as It Follows the Annual Cycle

Enough about slowdowns and recession. August is typically a roller-coaster month in the equity markets and August 2019 didn’t disappoint in that regard. The bond markets’ inverted yield curve persisted into September and that’s never a good sign. We’re moving on. Preliminary data show August’s deal volume wasn’t so bad, considering how most of 2019 […]

gene-editing
gene-editing

Merck Buys Immunotherapy Firm Immune Design

Merck & Co., Inc. (NYSE: MRK), the global healthcare and pharmaceutical company, has acquired Immune Design (NASDAQ: IMDZ) for $300 million. Merck will buy all outstanding shares of Immune Design at a value of $5.85 per share. With reported revenue of only $2 million, Immune Design’s price tag equals close to a 136x EBITDA multiple. Out of […]

gene-editing
gene-editing

Bristol-Myers Squibb Surprises with Celgene Deal

Twas a week before the J.P. Morgan Healthcare Summit, and everything was quiet on the life sciences front. December deal-making hit a wall, with pharmaceutical deals falling 50% compared with last December. Then came Bristol-Myers Squibb‘s (NYSE: BMY) announcement it was acquiring Celgene Corporation (NASDAQ: CELG) for approximately $90 billion. This isn’t the biggest pharma […]

Chromosomes
Chromosomes

Deal of the Week: Celgene/Impact

Biotechnology deals are off to a strong start in 2018, thanks to the Biotech Showcase 2018 held every year alongside the J.P. Morgan Healthcare Conference. In the first two weeks, 16 transactions were made public. This year, the Showcase registration desk was just getting into full swing on Sunday, January 7, when Celgene Corp. (NASDAQ: CELG) […]

Q1:17 Biotechnology Deals Keep Climbing

Biotechnology deal activity has climbed steadily over the past five quarters. The sector reached 62 transactions in Q1:17, an increase of 13% over the previous quarter and up 94% year-over-year. The total is 31% of the 203 deals announced in the previous 12 months. M&A in this sector will remain active for years to come, […]

Pfizer Buys Medivation and More

Forget those early- to mid-stage clinical candidates. Pfizer Inc. (NYSE: PFE) jumped the line with its $13.5 billion deal for oncology drug maker Medivation Inc. (NASDAQ: MDVN). The target’s primary product is XTANDI® (enzalutamide), an androgen receptor inhibitor, the leading novel hormone therapy for the treatment of prostate cancer. Pfizer will pay $81.50 per share in […]

Health Care M&A Exploded in July

The fireworks didn’t end on the Fourth of July, at least for the health care M&A market. Preliminary data shows deal volume rose 16% to 121 deals, compared with June’s 104 deals. Thanks to the mega-deals among health insurers and generic drug makers, deal value was approximately $166.6 billion, up 883% over June’s $16.9 billion. […]

Celgene Continues Its Buying Spree

Celgene Corporation (NASDAQ: CELG) made yet another major acquisition last week, picking up Receptos, Inc. (NASDAQ: RCPT) for $7.2 billion. The acquisition significantly boosts Celgene’s Inflammation and Immunology portfolio with the addition of Receptos’ lead product candidate, Ozanimod, which is in Phase 3 tests to treat immune-inflammatory indications in irritable bowel syndrome and relapsing multiple […]

Juno Therapeutics Teams up with Celgene

Celgene Corporation (NASDAQ: CELG) made a big bet on a small company last week, when it agreed to pay nearly $1 billion to Juno Therapeutics (NASDAQ: JUNO) for a 10-year collaboration on immunotherapies targeting cancer and autoimmune diseases. The real price is $999,803,496 and consists of an upfront payment of $150 million, and the purchase […]